Does Linezolid Inhibit Its Own Metabolism?—Population Pharmacokinetics As a Tool to Explain the Observed Nonlinearity in Both Healthy Volunteers and Septic Patients
Open Access
- 16 July 2007
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 35 (10), 1816-1823
- https://doi.org/10.1124/dmd.106.013755
Abstract
Few studies investigating the population pharmacokinetics of linezolid in critically ill patients have been reported, yielding controversial results. Therefore, a population pharmacokinetic analysis using NONMEM was performed to thoroughly understand the pharmacokinetics of unbound linezolid in plasma. Data were obtained from 10 healthy volunteers and 24 septic patients. Intensive sampling was performed after single and multiple dosing. The pharmacokinetics of unbound linezolid was best described by a two-compartment model with an absorption rate constant (KA, 1.81 h-1), clearance (CL, 11.1 l/h), volumes of distribution (V2 and V3, 20.0 and 28.9 liters, respectively), and intercompartmental clearance Q, 75.0 l/h). However, clearance was inhibited over time to 76.4% of its original value, dependent on the concentration in an empirical inhibition compartment. Overall, imprecision of parameter estimates was low to moderate. Comparison of goodness of fit graphics and of the predictive performance revealed that the presented model was superior to previously published models using linear elimination or parallel linear and Michaelis-Menten elimination and also to other of our own investigated model alternatives. The observed nonlinearity in linezolid pharmacokinetics might be a result of an inhibition of the formation of the major linezolid metabolite due to the inhibition of respiratory chain enzyme activity. To our knowledge, this study presents the first attempt to mechanistically explain the observed nonlinearity in linezolid pharmacokinetics. Finally, simulations demonstrated that the model might also serve as a tool to predict concentration-time profiles of linezolid, thus providing a rationale for a more targeted antimicrobial therapy.Keywords
This publication has 28 references indexed in Scilit:
- Pharmacokinetics of Unbound Linezolid in Plasma and Tissue Interstitium of Critically Ill Patients after Multiple Dosing Using MicrodialysisAntimicrobial Agents and Chemotherapy, 2006
- Linezolid-Induced Inhibition of Mitochondrial Protein SynthesisClinical Infectious Diseases, 2006
- Absolute Bioavailability and Pharmacokinetics of Linezolid in Hospitalized Patients Given Enteral FeedingsAntimicrobial Agents and Chemotherapy, 2005
- Covariate Detection in Population Pharmacokinetics Using Partially Linear Mixed Effects ModelsPharmaceutical Research, 2005
- Development of a liquid chromatography method for the determination of linezolid and its application to in vitro and human microdialysis samples.Journal of Chromatography B, 2003
- Pharmacokinetics of Linezolid in Subjects with Renal DysfunctionAntimicrobial Agents and Chemotherapy, 2003
- In vitro susceptibilities of zygomycetes to conventional and new antifungalsJournal of Antimicrobial Chemotherapy, 2002
- Oxazolidinone antibioticsThe Lancet, 2001
- Surgery and intensive care procedures affect the target site distribution of piperacillinCritical Care Medicine, 2000
- The ACCP-SCCM Consensus Conference on Sepsis and Organ FailureSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1992